Status:
COMPLETED
PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples
Lead Sponsor:
Boston Medical Center
Collaborating Sponsors:
Gilead Sciences
Conditions:
PrEP for Conception Purposes
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to observe patient response to current clinical practice utilizing TRUVADA (emtricitabine and tenofovir disoproxil fumarate) for Pre-Exposure Prophylaxis (PrEP) amongst HI...
Detailed Description
Based on CDC's guidance on PrEP as well as results of randomized controlled trials, the U.S. Food and Drug Administration (FDA) approved this daily medication (comprised of one pill) to reduce the ris...
Eligibility Criteria
Inclusion
- Between the ages of 18 to 40 years
- In relationship with HIV-positive male
- Chosen to take PrEP for conception after completing counseling with health care provider
Exclusion
- HIV-positive
- In relationship with HIV-negative female
- Partner has chosen to take PrEP for conception after completing counseling with health care provider
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02233192
Start Date
July 1 2014
End Date
June 15 2017
Last Update
July 7 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60201
2
The Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287
3
Boston University Medical Center
Boston, Massachusetts, United States, 02118
4
Drexel University
Philadelphia, Pennsylvania, United States, 19102